Equities researchers at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research report issued on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Up 16.8 %
Shares of EVOK opened at $0.55 on Thursday. The company has a market cap of $4.66 million, a PE ratio of -0.24 and a beta of 0.22. The stock has a 50-day moving average price of $0.63 and a 200-day moving average price of $0.93. Evoke Pharma has a 12-month low of $0.42 and a 12-month high of $2.42.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter. The business had revenue of $1.68 million for the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative return on equity of 517.99%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- The 3 Best Blue-Chip Stocks to Buy Now
- United Airlines Soars on Earnings Beat
- Dividend Capture Strategy: What You Need to Know
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What is Short Interest? How to Use It
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
